HeimALMRY • OTCMKTS
add
ALMIRALL S A Unsponsored ADR
Viðskiptafréttir
Barron's
fyrir 35 mínútum
S&P 500 Futures Up in Premarket Trading; Regencell Bioscience, EchoStar Lead
97,43%
6,83%
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (EUR) | mar. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 286,10 m. | 14,99% |
Rekstrarkostnaður | 157,80 m. | 12,55% |
Nettótekjur | 21,60 m. | 191,89% |
Hagnaðarhlutfall | 7,55 | 154,21% |
Hagnaður á hvern hlut | — | — |
EBITDA | 70,80 m. | 35,11% |
Virkt skatthlutfall | 39,66% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (EUR) | mar. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 374,40 m. | 19,12% |
Heildareignir | 2,40 ma. | 3,85% |
Heildarskuldir | 895,80 m. | 7,80% |
Eigið fé alls | 1,50 ma. | — |
Útistandandi hlutabréf | 213,47 m. | — |
Eiginfjárgengi | 1,50 | — |
Arðsemi eigna | 3,56% | — |
Ávöxtun eigin fjár | 4,58% | — |
Peningaflæði
Breyting á handbæru fé
| (EUR) | mar. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | 21,60 m. | 191,89% |
Handbært fé frá rekstri | 26,40 m. | 12,82% |
Reiðufé frá fjárfestingum | -19,80 m. | 77,55% |
Reiðufé frá fjármögnun | -9,30 m. | -5,68% |
Breyting á handbæru fé | -2,70 m. | 96,33% |
Frjálst peningaflæði | 18,91 m. | 130,10% |
Um
Almirall, S.A. is a Spanish pharmaceutical company dedicated to medical dermatology, with headquarters in Barcelona, founded in 1944.
In 2023, the company generated total revenues of €898.8 million and was the leading European company in medical dermatology.
With approximately 1,904 employees, it has a direct presence in 20 countries through its 15 subsidiaries in Europe and the USA. Wikipedia
Framkvæmdastjóri
Stofnsett
1944
Vefsvæði
Starfsfólk
2.026
